|
|
 | | | |
- close
- close
- close
- close
| |||||||||
These excerpts taken from the CYCC 10-K filed Mar 31, 2009. Sales and
Marketing
We currently have a nine person pharmaceutical commercial sales
organization marketing our ALIGN products. We expect to expand
our sales and commercialization group to support our products
that may be commercialized for oncology/hematology indications
and possibly other therapeutic areas. We intend to market and
sell directly products for indications addressing modest patient
populations. For products with indications addressing large
patient populations we may partner with other pharmaceutical
companies. In addition, we may accelerate the expansion of our
commercial organization to take advantage of any product
in-licensing and acquisition opportunities that we may we elect
to pursue.
Sales and
Marketing
We currently have a nine person pharmaceutical commercial sales
organization marketing our ALIGN products. We expect to expand
our sales and commercialization group to support our products
that may be commercialized for oncology/hematology indications
and possibly other therapeutic areas. We intend to market and
sell directly products for indications addressing modest patient
populations. For products with indications addressing large
patient populations we may partner with other pharmaceutical
companies. In addition, we may accelerate the expansion of our
commercial organization to take advantage of any product
in-licensing and acquisition opportunities that we may we elect
to pursue.
Sales and Marketing We currently have a nine person pharmaceutical commercial sales organization marketing our ALIGN products. We expect to expand our sales and commercialization group to support our products that may be commercialized for oncology/hematology indications and possibly other therapeutic areas. We intend to market and sell directly products for indications addressing modest patient populations. For products with indications addressing large patient populations we may partner with other pharmaceutical companies. In addition, we may accelerate the expansion of our commercial organization to take advantage of any product in-licensing and acquisition opportunities that we may we elect to pursue. Sales and Marketing We currently have a nine person pharmaceutical commercial sales organization marketing our ALIGN products. We expect to expand our sales and commercialization group to support our products that may be commercialized for oncology/hematology indications and possibly other therapeutic areas. We intend to market and sell directly products for indications addressing modest patient populations. For products with indications addressing large patient populations we may partner with other pharmaceutical companies. In addition, we may accelerate the expansion of our commercial organization to take advantage of any product in-licensing and acquisition opportunities that we may we elect to pursue. | EXCERPTS ON THIS PAGE:
RELATED TOPICS for CYCC: |
| |||||||
